Compugen Compugen (CGEN) announced the presentation of new research data that further support PVRIG as a potentially promising target for cancer immunotherapy. These data suggest that PVRIG inhibition may enhance T cell priming and infiltration into tumors and provide further evidence supporting the potential advantages of targeting PVRIG alone and in combination with TIGIT and PD-1 inhibitors, in tumors . . . This content is for …

Exelixis and Bristol-Myers Squibb sNDA and sBLA Accepted by the FDA Exelixis (EXEL) and Bristol-Myers Squibb (

Bristol-Myers Squibb Increased activity being observed at Bristol-Myers Squibb (BMY) is aimed at further empowering the firm's various franchises. It all started with the firm’s attempt to empower its oncology franchise with the creation and approval of its checkpoint protein inhibitor Opdivo (nivolumab) - a programmed Death-1 (PD-1) inhibitor. This antibody has been the most successful attempt . . . This content is for paid …

Why Agenus Stock Rallied Yesterday On September 2, 2020 we posted an article about Agenus (AGEN) under Trick or Trade titled, “

Compugen Announced Encouraging News from Its Phase 1/2 Study of COM701 Compugen (CGEN) announced that the first patient has been dosed in the Phase 1/2 study of the triple combination of COM701 - Compugen’s first-in-class anti-PVRIG antibody, with Bristol Myers Squibb’s  (

Exelixis Announces Submission of sNDA to US FDA for CABOMETYX® Exelixis (EXEL) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA for CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) for patients with advanced renal cell carcinoma (RCC). From Exelixis According to Gisela Schwab, M.D., President, Product Development and Medical . . . This content is for paid subscribers. Please click here …

CureVac is Publicy Trading on the NASDAQ CureVac is now publicly trading on the NASDAQ stock exchange with the symbol CVAC, as of August 14, 2020. We assume you must have heard the name of this firm by now and of America’s attempts to buy it for its messenger ribonucleic acid (mRNA) approach. This approach creates vaccines and drugs inside the living bodies. CureVac (CVAC) mRNA-derived …

Compugen Compugen (CGEN) cancer immunotherapy’s predictive target computational discovery platforms enabled it to identify two checkpoint proteins, PVRIG and TIGIT, when nobody else could. Compugen’s technological capability has also enabled it to create therapeutic inhibitors of its two discovered targets. The discoveries happened to be important in improving cancer immunotherapy. The lead therapeutic candidate, COM701 . . . This content is for paid subscribers. Please …

Compugen IND Application for Triple Combination Study Cleared by the US FDA The U.S. Food and Drug Administration has cleared Compugen’s (CGEN) investigational new drug (IND) application for its Phase 1/2 study evaluating the triple combination of COM701, Compugen’s first-in-class anti-PVRIG antibody, OPDIVO® (nivolumab) -- Bristol Myers . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Nektar Therapeutics Nektar Therapeutics (NKTR) announced the publication of Phase 1 clinical data for its immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) + nivolumab, in Cancer Discovery -  a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery informed that BEMPEG administered as monotherapy . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Bristol-Myers Squibb and bluebird bio  Bristol-Myers Squibb (BMY) and bluebird bio (

CytomX Therapeutics CytomX (CTMX) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® technology platform for cancer treatments. CytomX’s Probody therapeutics remain inactive until they are activated by proteases in the tumor microenvironment.   Why This is Important By remaining inactive until activated by the cancers’ microenvironment’s proteases, the Probody therapeutics minimizes the active drug’s toxicity …

Exelixis Rallying from CheckMate-9ER Trial Results Exelixis (EXEL) and Bristol-Myers Squibb (

Prohost Letter #439 The Coronavirus Outbreak - COVID-19 The news announced that the coronavirus (now known as COVID-19) outbreak would affect not only people’s health and survival but the world’s economy, Wall Street’s performance, and especially the international giant industrial firms that are committed to China. British AstraZeneca (AZN

Gilead Stock Is UP Gilead Sciences' (GILD) provided its antiviral experimental drug remdesivir to physicians for a small number of patients infected with the 2019 novel coronavirus (2019-nCoV) as a possible emergency savior . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Time to Remember Compugen The time has ripened for our readers and biotech investors to remember what we posted in the past years about Compugen (CGEN). The importance of the reminder is that the firm has taken a long time to bring its target discoveries and its targeted treatments into clinical trials whose preliminary results have demonstrated promise. Compugen

Nektar in the NEWS The FDA's Anesthetic and Analgesic Advisory Committee (AADPAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) unanimously voted no regarding the approval of Nektar Pharmaceuticals’ (NKTR) New Drug Application (NDA) for its opioid product oxycodegol (formerly NKTR-181). In a short

Nektar Therapeutics and Bristol-Myers Squibb Agreement Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) announced their agreement for a new joint development plan aimed at advancing the combination of Nektar’s bempegaldesleukin (bempeg) + Bristol-Myers’ Opdivo (nivolumab) into multiple new registrational trials. The decision is based on a revision of the strategic collaboration agreement. It includes a new plan where both firms will expand the active clinical development …

Nektar Therapeutics Presents NKTR-255 at ASH Nektar Therapeutics’ (NKTR) IL-15 agonist investigational candidate NKTR-255 presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition have been promising. Positive data presented from Fred Hutchinson Cancer Research Center preclinical studies conducted in collaboration with researchers from the Dana-Farber Cancer Institute and more. NKTR-255 is currently . . . This content is for paid subscribers. …

Firstly, Forty-Seven and IVERIC bio  We remind that the two condemned stocks Forty-Seven (FTSV) and  IVERIC bio (